ALK and non-small cell lung carcinoma: The oncogenic mechanism of ALK-A was first described in 2002 in neuroblastoma cell lines and has been discovered also in NSCLC, while point mutations of the ALK locus, most commonly in the kinase domain, have been reported mostly in patients with neuroblastoma and thyroid cancer [15,16].